Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 May;6(3):115-27.
doi: 10.1177/1758834014522491.

Recent advances in the treatment of gastrointestinal stromal tumors

César Serrano  1 , Suzanne George  2
Affiliations
Review

Recent advances in the treatment of gastrointestinal stromal tumors

César Serrano et al. Ther Adv Med Oncol. 2014 May.

Abstract

Constitutively activating mutations in the KIT and platelet-derived growth factor receptor α (PDGFRA) RTKs play a crucial role in the biology of gastrointestinal stromal tumors (GISTs), and this disease has served as an effective model for targeting gain-of-function kinase mutations in cancer. Imatinib has entered the clinical arena in the last decade and substantially improved the outcome in these formerly untreatable cancers. However, most advanced GISTs responding to imatinib progress within 2-3 years due to heterogeneous subclones harboring a range of imatinib-resistant secondary KIT mutations. Sunitinib, and more recently, regorafenib, have obtained US Food and Drug Administration approval for the treatment of GISTs after imatinib failure, and thus expanded the treatment options in resistant disease. Within this framework, we present an evaluation of current GIST management, emphasizing the most recent advances in the field together with a discussion on future steps to be taken in refractory disease.

Keywords: c-KIT; gastrointestinal stromal tumors; imatinib; masitinib; nilotinib; regorafenib; sorafenib; sunitinib.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declare no conflicts of interest in preparing this article.

Figures

Figure 1.
Figure 1.
KIT activation in gastrointestinal stromal tumors. ATP, adenosine triphosphatase.
See this image and copyright information in PMC

References

    1. Antonescu CR., Besmer P., Guo T., Arkun K., Hom G., Koryotowski B., et al. (2005) Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res, 11, 4182–4190 - PubMed
    1. Bantscheff M., Eberhard D., Abraham Y., Bastuck S., Boesche M., Hobson S., et al. (2007) Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol, 25, 1035–1044 - PubMed
    1. Bauer S., Duensing A., Demetri GD., Fletcher JA. (2007) KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Oncogene, 26, 7560–7568 - PubMed
    1. Bauer S., Yu LK., Demetri GD., Fletcher JA. (2006) Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res, 66, 9153–9161 - PubMed
    1. Debiec-Rychter M., Cools J., Dumez H., Sciot R., Stul M., Mentens N., et al. (2005) Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology, 128, 270–279 - PubMed

LinkOut - more resources